Richard C. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, and Executive Vice Chairman at Sana Biotechnology. Previously, Professor Mulligan was the Mallinckrodt Professor of Genetics at Harvard Medical School, and Director of the Harvard Gene Therapy Initiative, an integrated effort amongst basic science and clinical investigators at Harvard University and its Affiliated Hospitals directed towards the pre-clinical and clinical evaluation of novel gene-based therapies for inherited and acquired diseases. Professor Mulligan received his B.S. degree from Massachusetts Institute of Technology (MIT), and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine, where he studied under Nobel Laureate Paul Berg. After receiving postdoctoral training at the Center for Cancer Research at MIT with Nobel Laureates David Baltimore and Phillip Sharp, Professor Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Harvard and Children’s Hospital in 1996. From May 2013 to December 2016, Professor Mulligan was Founding Partner and Senior Managing Director of Sarissa Capital Management LP, a registered investment advisor,  and Portfolio Manager at Icahn Capital LP from March, 2017 until November, 2018. Professor Mulligan’s scientific accomplishments relate primarily to the development of methods for introducing genes into mammalian cells and the application of gene transfer technology to both the study of basic biology and the practice of gene therapy.